NCT02391038 (Clinical Trial/ Indusatumab vedotin / MLN0264)

Study Title
MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C (NCT02391038)

Trial Description
The purpose of this study is to evaluate the effects of MLN0264 (Indusatumab vedotin) in previously treated Asian patients with Advanced Gastrointestinal (GI) Carcinoma (Phase I) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase II) Expressing Guanylyl Cyclase C (GCC).

This trial is sponsored by Millennium Pharmaceuticals/ Seattle Genetics [1]

Study Data

  • Condition: Gastric or Gastroesophageal Junction Adenocarcinoma
  • Interventions:
    • Drugs used in this trial
      • MLN0264 (Indusatumab vedotin)
  • Phase: I & II
  • Estimated Enrollment: 95
  • Start: January 2015
  • Estimated Completion: October 2018

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: September 29, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.